Leonard Reyno
Known title: Chief Medical OfficerCIK: 0001528716
Associated companies
Transaction History
| CCCC | ▲ Buy | Option Exercise | 15,325 | $0 | 7/10/2026 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 7,397 | $30K | 7/10/2026 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 30,950 | $0 | 2/14/2026 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 16,579 | $31K | 2/14/2026 | View on chart |
| CCCC | ▲ Buy | Grant | 240,000 | $0 | 2/13/2026 | View on chart |
| CCCC | ▼ Sell | Open Market | 10,000 | $22K | 1/16/2026 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 7,382 | $15K | 7/10/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 87,100 | $0 | 2/14/2025 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 5,145 | $16K | 2/14/2025 | View on chart |
| CCCC | ▼ Sell | Tax Withholding | 6,191 | $31K | 7/10/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 36,700 | $0 | 2/14/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 61,300 | $0 | 7/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.